Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old

Simple item page
dc.contributor.authorHillman R.J.
dc.contributor.authorGiuliano A.R.
dc.contributor.authorPalefsky J.M.
dc.contributor.authorGoldstone S.
dc.contributor.authorMoreira Jr. E.D.
dc.contributor.authorVardas E.
dc.contributor.authorAranda C.
dc.contributor.authorJessen H.
dc.contributor.authorFerris D.G.
dc.contributor.authorCoutlee F.
dc.contributor.authorMarshall J.B.
dc.contributor.authorVuocolo S.
dc.contributor.authorHaupt R.M.
dc.contributor.authorGuris D.
dc.contributor.authorGarner E.I.O.
dc.date.accessioned2012-04-12T08:17:37Z
dc.date.available2012-04-12T08:17:37Z
dc.date.issued2012
dc.description.abstractHuman papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
dc.identifier.citationClinical and Vaccine Immunology
dc.identifier.citation19
dc.identifier.citation2
dc.identifier.citation261
dc.identifier.citation267
dc.identifier.issn15566811
dc.identifier.other10.1128/CVI.05208-11
dc.identifier.urihttp://hdl.handle.net/10019.1/20503
dc.titleImmunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications